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AL amyloidosis is characterised by an underlying
plasma cell clone producing structurally abnormal
monoclonal free light chains (FLCs) which mis-fold and
deposit as amyloid ﬁbrils leading to progressive tissue
damage. Detection and serial measurements of serum
FLCs are critical in determining prognosis and in asses-
sing response to treatment. All current immunoassays for
quantifying amyloidgenic monoclonal FLCs also measure
the normal polyclonal FLC background—a major limita-
tion for a disease where even low-level monoclonal FLCs
are crucially important. We describe a novel mass spec-
trometry (MS) method for accurate detection of mono-
clonal free light chains in patients with systemic AL
amyloidosis.
MS is a technique used to sort a sample based on the
ratio of mass to charge. MS has recently been explored in
the assessment of FLCs both in the setting of AL amy-
loidosis and other plasma cell dyscrasias;1 the theory
being that each monoclonal FLC is made of a unique
amino acid sequence, with a unique molecular mass.
Various different MS techniques exist. The clonotypic
peptide MS approach relies on the digestion of serum
immunoglobulins with trypsin prior to analysis by MS2.
Although this approach is sensitive3, the technique relies
on the initial identiﬁcation of a peptide from the patient’s
monoclonal protein (M protein)/FLC, which can then be
serially monitored over time. An alternative approach is
the monoclonal immunoglobulin rapid accurate mole-
cular mass (miRAMM) technique which, rather than
analysing tryptic peptides, utilises a reducing agent to
dissociate the heavy and light chains allowing MS analysis
of intact proteins. This allows both post-translational
modiﬁcation change to be observed1 and minor FLC sub-
clones to be monitored1. The matrix-assisted laser deso-
rption ionization time of ﬂight mass spectrometry
(MALDI-TOF or MASS-FIX) is a high throughput ver-
sion of miRAMM4 which has been explored in a group of
patients with plasma cell dyscrasia and has demonstrated
comparable sensitivity to existing protein electrophoresis
and serum FLC methods1.
Here we report on a novel and simple to use MALDI-
TOF-MS method for monoclonal FLC detection (FLC-
MS) in a small series of patients with systemic AL
amyloidosis.
We included 17 serial patients with systemic AL amy-
loidosis, one patient with amyloid of uncertain type, and
two MGUS (monoclonal gammopathy of undetermined
signiﬁcance) patients, all referred to the UK National
Amyloidosis Centre (UK-NAC) (Table 1). Two of the 17
patients with AL amyloidosis were selected with samples
at diagnosis and post-treatment when in complete
remission (CR), but with known presence of minimal
residual disease (MRD) on bone marrow. Sera samples
from healthy donors (n= 17), with normal kappa and
lambda ratios, were also analysed using sheep polyclonal
antisera (Binding-Site, Birmingham, UK) with equivalent
speciﬁcity for comparison (data not shown). A diagnosis
of AL amyloidosis was conﬁrmed by demonstration of
characteristic birefringence under cross-polarized light
with Congo-red staining on a tissue biopsy, and AL typing
was conﬁrmed by immunohistochemistry or by laser
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capture mass spectrometry. All patients had detailed
baseline assessments of organ function including serum
FLC measurements and imaging. Organ involvement and
organ response was deﬁned according to the international
amyloidosis consensus criteria5.
Commercially available paramagnetic microparticles
were covalently coated with polyclonal sheep antibodies
monospeciﬁc for human kappa FLCs (anti-free κ) and
lambda FLCs (anti-free λ) (Binding-Site, Birmingham,
UK). The microparticles were incubated with patient sera,
washed and treated with acetic acid (5% v/v), containing
tris(2-carboxyethyl)phosphine (TCEP) (20 mM), in order
to elute FLCs in monomeric form. Mass spectra were
acquired on a Microﬂex LT/SH smart matrix-assisted
laser desorption ionization time-of-ﬂight mass spectro-
meter (MALDI-TOF-MS; Bruker, GmbH). Approval for
analysis and publication was obtained from the NHS
institutional review board, and written consent was
obtained from all patients in accordance with the
Declaration of Helsinki.
The baseline characteristics of patients are presented in
Table 1. The FLC-MS assay conﬁrmed normal polyclonal
kappa and lambda FLC expression in the 17 controls. The
FLC-MS assay correctly identiﬁed the presence and type
of monoclonal FLC in 3/3 (100%) kappa and 14/14 (100%)
lambda AL amyloidosis patients (Fig. 1a–c). The FLC-MS
assay did not detect any monoclonal FLC in one patient
with amyloid of uncertain type, where amyloid ﬁbril type
remained unclear by both immunohistochemistry and
laser capture mass spectrometry, suggesting against a
diagnosis of AL amyloidosis.
In two patients, FLC-MS identiﬁed presence of mono-
clonal lambda FLC with the same molecular mass
(respectively) with paired samples at diagnosis and fol-
lowing achieving a serological CR post-treatment (Fig. 1d)
(in both cases with normal FLC (lambda light chains <
20mg/L in each case), and no monoclonal band in
immunoﬁxation in serum and urine). Both patients
achieved an organ response to treatment. The ﬁrst patient
had renal involvement alone and achieved a renal
response with a 61% reduction in proteinuria, but with
persistent proteinuria of 2.1 g/day. The second patient
had cardiac involvement and achieved a cardiac response
with an 88% reduction, and normalisation, of NT-proBNP
levels. Both patients had had a bone marrow examination
with next generation sequencing (NGS) and next gen-
eration ﬂow cytometry (NGF), respectively, showing per-
sistent MRD in the bone marrow to the level of < 40 cells/
106.
In lambda AL amyloidosis patients with renal involve-
ment, the monoclonal lambda FLC tended to display a
“heavy” molecular mass (m/z[2+]= 11646.2 ± 23.6) com-
pared to normal polyclonal lambda (m/z[2+]= 11428.1 ±
4.9). Conversely, patients with cardiac involvement
exhibited a monoclonal lambda FLC with a “light” mass
(m/z[2+]= 11312.8 ± 16.1) relative to the normal control
(Fig. 1e). This result must be interpreted with caution
given the small sample size of this study, but we hope to
conﬁrm and explore the signiﬁcance of this ﬁnding in a
larger cohort of patients. In patients with kappa AL
amyloidosis, whilst a monoclonal peak was apparent, no
substantial difference in FLC molecular mass was
observed when compared to normal sera (Fig. 1e).
This proof of concept study demonstrates the utility of a
novel MALDI-TOF-MS technique to detect and char-
acterise monoclonal FLC in AL amyloidosis. The Mayo
group has led the way in MASS-FIX for detection of
serum monoclonal immunoglobulins and FLCs, with
sensitivities similar to current electrophoretic and
nephelometric/turbidimetric methods1. The FLC-MS
method described here substantially extends on previous
ﬁndings by demonstrating i) high diagnostic sensitivity
and speciﬁcity, in this small sample; 2) 100% concordance
with immunohistochemistry results; and iii) crucially
identifying monoclonal light chains in patients in ser-
ological CR but with persistent MRD.
Table 1 Baseline characteristics of amyloidosis patients,
n= 18*
n (%) Median (range)
Organs involved: 2 (1–4)
Cardiac 14 (77)
Renal 8 (44)
Autonomic and soft tissue 3 (17)
Peripheral nerve 1 (6)
Liver 0 (0)
NT-proBNP, ng/L 3761 (245–25348)
Troponin T, ng/L 35 (8–170)
Serum albumin, g/L 37 (19–45)
eGFR, mL/min 62 (10–100)
Amyloid type:
AL kappa 3 (17)
AL lambda 14 (78)
Uncertain 1 (6)
iFLC kappa, mg/L 78 (73–440)
iFLC lambda, mg/L 185 (44–1023)
dFLC, mg/L 118 (33–1015)
Monoclonal Intact Ig 14(77)
*two MGUS patients not included in the table
NT-proBNP indicates N-terminal pro b-type natriuretic peptide, eGFR estimated
glomerular ﬁltration rate, AL light chain amyloidosis, iFLC involved free light
chain, dFLC difference between involved and uninvolved free light chain, Ig
immunoglobulin
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In conclusion, the unique molecular location of FLC on
MS can facilitate the detection of monoclonal amyloido-
genic FLCs which may allow more accurate monitoring
and more informed treatment decisions based on the
detection of monoclonal pathogenic FLC component. The
simplicity of this MALDI-TOF assay may allow for make
it easier to implement in routine laboratories (if the
ﬁndings are conﬁrmed in larger studies) and the ability of
MALDI-TOF MS to analyse intact FLCs may help in
capturing crucial post-translational modiﬁcations, which
may be key in the pathogenicity of FLC in AL amyloidosis.
A study of a large cohort of uniformly treated patients
with AL amyloidosis is in progress to conﬁrm our ﬁndings
and to assess the impact of FLC-MS on survival and organ
response outcomes.
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Fig. 1 Mass spectra and m/z values for FLC in patients with AL amyloidosis. Examples of kappa and lambda FLC molecular mass of a a normal
control; b a patient with lambda amyloidosis and renal involvement demonstrating a “heavy mass” monoclonal FLC; c a patient with lambda
amyloidosis and cardiac involvement demonstrating a “light mass” monoclonal FLC; d a patient with lambda amyloidosis and renal involvement in
haematological complete response (CR) after treatment, demonstrating a “heavy mass” monoclonal FLC; e comparative median m/z FLC values from
control, kappa and lambda AL amyloidosis patients; lambda FLC values for patients with cardiac and renal involvement are presented. Statistical
differences relative to controls were assessed by Mann-Whitney U-test: p < 0.05 indicates signiﬁcance. Values for m/z represent the 2+ charged ions.
Mass spectra for kappa FLCs are shown in green; for lambda FLC in purple
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